Capricor Therapeutics Faces Class Action Lawsuit as Investors Claim Misleading Statements Led to Financial Losses
Los Angeles, Calif. — A class action lawsuit has been initiated against Capricor Therapeutics, Inc. (CAPR) in response to claims that the company’s stock was sold at inflated prices. Filed by the law firm Levi & Korsinsky on July 17, 2025, the lawsuit alleges that shareholders purchased stock during a defined class period from October 9, 2024, to July 10, 2025, without full knowledge of the company’s actual financial condition. Affected investors are being encouraged to seek information on participation in the action. Capricor Therapeutics is engaged in the development of innovative cell and exosome-based … Read more